According to KEGG analysis, SLC25A32-correlated genes were enriched in the PI3K-AKT signaling pathway. It is widely known that aberrant activation of the PI3K-AKT-mTOR signaling pathway increases the malignant phenotype of malignancies. Therefore, we examined how ectopic SLC25A32 expression affected the expression of p-AKT (Ser473), which is essential for the activity and function of AKT. As shown in Fig.
6A, overexpression of SLC25A32 increased p-AKT (Ser473) and p-mTOR (Ser2448) protein expression in GBM#BG5 cells (Fig.
6A), whereas knockdown SLC25A32 decreased p-AKT (Ser473) and p-mTOR (Ser2448) protein expression in both LN229 and GBM#P3 cells (Fig.
6A). Using SC79, a specific AKT activator, to counteract the stimulation of the PI3K/AKT pathway and siSLC25A32-induced AKT inactivation, we further assessed the significance of PI3K-AKT signaling on SLC25A32-induced cell proliferation and invasion. (Fig.
6B). When co-treated with SC79 (10 µg/ml), the inhibition of GBM cell growth caused by SLC25A32 knockdown was rescued as proven by CCK8 and Edu assays (Fig.
6C-F). AKT activation caused by SLC25A32 and the stimulation of the PI3K-AKT pathway were both prevented by the administration of the PI3K inhibitor LY294002. In GBM cells, cotreatment with LY294002 (10 mM) dramatically reduced p-AKT and p-mTOR. (Fig.
6B). Consistently, SLC25A32-induced GBM#BG5 cell proliferation were reversed by targeted inhibition using LY294002 (Supplementary Fig.
1E, F). We then confirmed that SC79 could rescue GBM invasion decline caused by SLC25A32 knockdown by Transwell assay, 3D sphere invasion assay and ex vivo co-culture invasion model (Fig.
7A, B, D), indicating that SLC25A32 also increased GBM invasion through the PI3K-AKT-mTOR signaling pathway. Consequently, LY294002 abolished the effect of SLC25A32 overexpression on GBM#BG5 cell invasion (Fig.
7C, E). Overall, our results showed that SLC25A32 stimulates PI3K/AKT pathway activation, which leads to GBM cell proliferation and invasion.